At two years of follow-up, patients with a poorly functioning tricuspid valve in the heart who received the best available ...

TRILUMINATE's primary endpoint was a hierarchical composite of death from any cause or tricuspid valve surgery, ...

system to treat tricuspid regurgitation (TR), or a leaky heart valve, offers substantial and sustained improvements in the severity of TR after two years. The results also demonstrate the TriClip ...

The recommendations are similar to those recently announced for TTVR, with the final NCD for T-TEER expected by July.

The tricuspid valve, one of four valves in the heart, controls blood flow from the right atrium (the heart’s upper-right chamber) to the right ventricle (the lower-right chamber).

Medtronic, Abbott and Boston Scientific had updates on their devices used in heart valve disease treatment at the event.

The primary endpoint was a composite of all-cause mortality or tricuspid valve surgery, heart failure hospitalizations, and quality-of-life improvement measured by the KCCQ score. TriClip is ...

Abbott today announced late-breaking data from its TRILUMINATEtm Pivotal trial that show the TriCliptm transcatheter edge-to-edge repair (TEER) system to treat tricuspid regurgitation (TR), or a leaky ...

The tricuspid valve used to be the 'forgotten valve ... and 55% had New York Heart Association class III/IV symptoms. By and large, the cohort had functional TR, about half presenting with ...

Ben McCullough, 76, received an EVOQUE heart valve last fall. On Wednesday, he got to thank the makers face-to-face.